Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease

Isabella Lurje; Frank Tacke

doi:10.21037/hbsn-24-568

Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease

Hepatobiliary Surg Nutr. 2024 Dec 1;13(6):1034-1037. doi: 10.21037/hbsn-24-568. Epub 2024 Nov 14.

Authors

Isabella Lurje^{1

2}, Frank Tacke¹

Affiliations

¹ Department of Hepatology and Gastroenterology, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany.
² Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.

No abstract available

Keywords: Metabolic dysfunction-associated steatotic liver disease (MASLD); metabolic dysfunctionassociated steatohepatitis (MASH); non-alcoholic fatty liver disease (NAFLD); nonalcoholic steatohepatitis (NASH); thyroid receptors.

Publication types

Editorial
Comment